Ludmila Smolyansky, identified as a trustee for the Ludmila Smolyansky Trust 2/1/05, has executed a significant reduction in her indirect holdings of Lifeway Foods, Inc. (NASDAQ:LWAY). The transactions, which took place over two consecutive days in late June 2026, involved the sale of 85,616 shares of the company's common stock. The aggregate value of these divestments stands at approximately $2,557,314, reflecting a substantial liquidation event by a member of the 10% owner group associated with the consumer staples company.
The sales were executed on June 24 and June 25, 2026. On the first day, June 24, Ms. Smolyansky sold 40,000 shares at a price of $30.12 per share. The following day, June 25, an additional 45,616 shares were offloaded at a weighted average price of $29.65 per share. These transactions were part of a broader series of sales conducted at prices ranging from $29.16 to $30.15. Following these divestments, Ms. Smolyansky’s indirect holdings in Lifeway Foods common stock total 607,207 shares. The timing of this sale is notable given the stock's recent momentum, which included a 19% return over the preceding week and a current trading price of $29.39. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, a metric that may provide context for the insider's decision to reduce positions.
The insider activity occurs against a backdrop of robust financial performance for Lifeway Foods. The company recently reported first-quarter 2026 results that surpassed market expectations. Earnings per share (EPS) were recorded at $0.30, significantly outpacing the forecasted $0.20. Revenue also exceeded projections, reaching $63 million, representing an 18.89% increase over expectations. This performance marks the company's 26th consecutive quarter of year-over-year growth, including record quarterly sales and sustained double-digit revenue expansion.
Despite these strong fundamentals, analyst sentiment regarding Lifeway Foods remains divided. Freedom Broker downgraded the stock from Buy to Hold, maintaining a price target of $34.00 per share. This downgrade occurred despite the company's record sales and growth trajectory. In contrast, Benchmark reaffirmed its Buy rating for the stock, setting a price target of $35.00. Benchmark cited strong fundamentals driven by growth in the company's flagship kefir product as the basis for its positive outlook. This divergence in analyst perspectives highlights the mixed market sentiment surrounding the company.